Payment overview · 2025
General Payments
$693.02
39 reported records · 7 companies
Healthcare provider profile · identity verified
William J Morris, MD
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBUS, OH · NPI 1912935453
Verified facts
What the public records show
CMS Open Payments records show William J Morris, MD received $693.02 in general payments during 2025 across 39 reported records.
ABBVIE INC. accounted for 37.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $261.24 | 37.7% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $217.26 | 31.4% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $83.50 | 12.1% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $80.22 | 11.6% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.32 | 2.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.69 | 2.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.79 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $693.02 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $146.46 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $112.65 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $99.34 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $79.04 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $72.96 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $69.55 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $66.62 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $66.62 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $41.35 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.87 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 101 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 127 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 65 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
101 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
127 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
154 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 807 | 217 |
| Atorvastatin Calcium | Atorvastatin Calcium | 763 | 216 |
| Losartan Potassium | Losartan Potassium | 627 | 149 |
| Omeprazole | Omeprazole | 531 | 141 |
| Alprazolam | Alprazolam | 475 | 79 |
| Metformin Hcl | Metformin Hcl | 434 | 110 |
| Gabapentin | Gabapentin | 377 | 77 |
| Lisinopril | Lisinopril | 364 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 325 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 314 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 297 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 287 | 65 |
| Glipizide | Glipizide | 275 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 255 | 49 |
| Tramadol Hcl | Tramadol Hcl | 239 | 45 |
| Trazodone Hcl | Trazodone Hcl | 235 | 64 |
| Furosemide | Furosemide | 227 | 61 |
| Simvastatin | Simvastatin | 217 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 203 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 52 |
| Citalopram Hbr | Citalopram Hydrobromide | 189 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 40 |
| Meloxicam | Meloxicam | 165 | 42 |
| Potassium Chloride | Potassium Chloride | 163 | 43 |
| Eliquis | Apixaban | 154 | 41 |
| Oxycodone Hcl | Oxycodone Hcl | 144 | 22 |
| Prednisone | Prednisone | 140 | 76 |
| Sertraline Hcl | Sertraline Hcl | 138 | 31 |
| Atenolol | Atenolol | 134 | 33 |
| Buspirone Hcl | Buspirone Hcl | 132 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 128 | 38 |
| Carvedilol | Carvedilol | 127 | 38 |
| Jardiance | Empagliflozin | 127 | 26 |
| Levofloxacin | Levofloxacin | 120 | 84 |
| Quetiapine Fumarate | Quetiapine Fumarate | 119 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 37 |
| Famotidine | Famotidine | 110 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 108 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 18 |
| Farxiga | Dapagliflozin Propanediol | 101 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 101 | 25 |
| Mirtazapine | Mirtazapine | 94 | 26 |
| Methylprednisolone | Methylprednisolone | 91 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 89 | 22 |
| Allopurinol | Allopurinol | 86 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 85 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 19 |
| Ozempic | Semaglutide | 81 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 80 | 47 |
| Trulicity | Dulaglutide | 80 | 17 |
| Clonidine Hcl | Clonidine Hcl | 79 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 79 | 47 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 23 |
| Lorazepam | Lorazepam | 77 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 18 |
| Montelukast Sodium | Montelukast Sodium | 73 | 21 |
| Clonazepam | Clonazepam | 72 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 12 |
| Nifedipine Er | Nifedipine | 68 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 67 | 13 |
| Spironolactone | Spironolactone | 67 | 20 |
| Linzess | Linaclotide | 65 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 15 |
| Levetiracetam | Levetiracetam | 63 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 62 | 15 |
| Bupropion Xl | Bupropion Hcl | 62 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 19 |
| Xarelto | Rivaroxaban | 61 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | suppressed |
| Naproxen | Naproxen | 58 | 19 |
| Promethazine Hcl | Promethazine Hcl | 56 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 32 |
| Diazepam | Diazepam | 53 | 12 |
| Granisetron Hcl | Granisetron Hcl | 53 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 52 | 13 |
| Ibuprofen | Ibuprofen | 52 | 18 |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 51 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | suppressed |
| Estradiol | Estradiol | 42 | 11 |
| Klor-Con M20 | Potassium Chloride | 41 | 13 |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 38 | suppressed |
| Amoxicillin | Amoxicillin | 37 | 16 |
| Gemfibrozil | Gemfibrozil | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 36 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | 11 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Novolog Flexpen | Insulin Aspart | 33 | 12 |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Torsemide | Torsemide | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 29 | 23 |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 12 |
| Latanoprost | Latanoprost | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 19 | 15 |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Clozapine | Clozapine | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $693.02 · 39 records | ABBVIE INC. | AIRSUPRA, Cologuard Collection Kit, FARXIGA, JARDIANCE, KRYSTEXXA, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, PAXLOVID, QULIPTA, UBRELVY, VRAYLAR, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error